Company News: Page (1) of 1 - 05/16/18 Email this story to a friend. email article Print this page (Article printing at page facebook

BerGenBio to Present Interim Clinical and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO

  (May 16, 2018)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Presentors,Business Issues,Presentation,Events,USA, Inc.,Medicine,Disease,Cancer,Surgery,Medication,Womens Health,Science,Medical,Cancer,Other,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved